Journal article
Modeling distinct osteosarcoma subtypes in vivo using Cre: Lox and lineage-restricted transgenic shRNA
AJ Mutsaers, AJM Ng, EK Baker, MR Russell, AM Chalk, M Wall, BJJ Liddicoat, PWM Ho, JL Slavin, A Goradia, TJ Martin, LE Purton, RA Dickins, CR Walkley
Bone | Published : 2013
Abstract
Osteosarcoma is the most common primary cancer of bone and one that predominantly affects children and adolescents. Osteoblastic osteosarcoma represents the major subtype of this tumor, with approximately equal representation of fibroblastic and chondroblastic subtypes. We and others have previously described murine models of osteosarcoma based on osteoblast-restricted Cre:lox deletion of Trp53 (p53) and Rb1 (Rb), resulting in a phenotype most similar to fibroblastic osteosarcoma in humans. We now report a model of the most prevalent form of human osteosarcoma, the osteoblastic subtype. In contrast to other osteosarcoma models that have used Cre:lox mediated gene deletion, this model was gen..
View full abstractGrants
Funding Acknowledgements
This work was supported by grants from the National Health and Medical Research Council of Australia (NHMRC; to C.W. and C.W./T.J.M.); AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research (C.W.); NHMRC Career Development Award (C.W.); NHMRC Senior Research Fellowship (LP.); Victorian Cancer Agency Early Career Seed Grant (C.W.); Victorian Cancer Agency Clinical Research Fellowship (M.W.); Cancer Therapeutics CRC (CTx) postgraduate scholarship (A.N.); Cure Cancer Australia Fellowship (E.B.); and in part by the Victorian State Government Operational Infrastructure Support Program (to St. Vincent's Institute). C.W. is the Philip Desbrow Senior Research Fellow of the Leukaemia Foundation.